angiotensin ii has been researched along with esculetin in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berger, M; Golub, M; Knoll, E; Nadler, JL; Natarajan, R; Nozawa, K; Stern, N; Tuck, ML; Yanagawa, N | 1 |
| Bagal, S; Gaikwad, AB; Goru, SK; Kadakol, A; Malek, V; Pandey, A | 1 |
| Gaikwad, AB; Goru, SK; Kadakol, A; Malek, V; Pandey, A | 1 |
| Ganji, SK; Gopoju, R; Kanugula, AK; Karnewar, S; Kotamraju, S; Kumar, JM; Prabhakar, S; Rangaraj, N; Tupperwar, N; Vasamsetti, SB | 1 |
| Gaikwad, AB; Goru, SK; Kadakol, A; Malek, V | 1 |
5 other study(ies) available for angiotensin ii and esculetin
| Article | Year |
|---|---|
Selective inhibition of angiotensin II-mediated vasoconstriction by lipoxygenase blockade.
Topics: Angiotensin II; Animals; Blood Pressure; Diastole; Femoral Artery; Flavanones; Flavonoids; In Vitro Techniques; Indomethacin; Lipoxygenase Inhibitors; Male; Norepinephrine; Potassium Chloride; Pyrazoles; Rats; Rats, Inbred Strains; Reference Values; Systole; Umbelliferones; Vasoconstriction | 1989 |
Esculetin attenuates alterations in Ang II and acetylcholine mediated vascular reactivity associated with hyperinsulinemia and hyperglycemia.
Topics: Acetylcholine; Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Antioxidants; Aorta; Blood Pressure; Diabetes Mellitus, Experimental; Hyperglycemia; Hyperinsulinism; Hypertension; Male; Peptidyl-Dipeptidase A; Rats, Wistar; Transforming Growth Factor beta; Umbelliferones | 2015 |
Insulin sensitizing and cardioprotective effects of Esculetin and Telmisartan combination by attenuating Ang II mediated vascular reactivity and cardiac fibrosis.
Topics: Angiotensin II; Animals; Benzimidazoles; Benzoates; Cardiotonic Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fibrosis; Heart Diseases; Insulin Resistance; Male; Rats; Rats, Wistar; Telmisartan; Treatment Outcome; Umbelliferones; Vasoconstriction | 2015 |
Mitochondria-targeted esculetin alleviates mitochondrial dysfunction by AMPK-mediated nitric oxide and SIRT3 regulation in endothelial cells: potential implications in atherosclerosis.
Topics: AMP-Activated Protein Kinases; Angiotensin II; Animals; Antioxidants; Aorta; Apolipoproteins E; Apoptosis; Atherosclerosis; Cell Survival; Cells, Cultured; Endothelial Cells; Humans; Hydrogen Peroxide; Male; Membrane Potential, Mitochondrial; Mice; Mice, Knockout; Microscopy, Confocal; Mitochondria; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase Type III; Oxidative Stress; Oxygen Consumption; Phosphorylation; RNA Interference; RNA, Small Interfering; Sirtuin 3; Umbelliferones | 2016 |
Esculetin ameliorates vascular perturbation by intervening in the occupancy of H2BK120Ub at At1, At2, Tgfβ1 and Mcp1 promoter gene in thoracic aorta of IR and T2D rats.
Topics: Acetylcholine; Angiotensin II; Animals; Aorta; Blood Vessels; Chemokine CCL2; Diabetes Mellitus, Type 2; Gene Expression Regulation; Hemodynamics; Histones; Insulin Resistance; Lysine; Muscle Relaxation; Myocardial Contraction; Promoter Regions, Genetic; Rats; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; RNA, Messenger; Transforming Growth Factor beta1; Ubiquitin; Umbelliferones | 2017 |